Pfizer Announces CFO Transition as Dave Denton Exits Company

Date:

Share post:

On 18th June Pfizer Inc. (NYSE: PFE) the American Pharmaceuticals major announced that Dave Denton currently working as Chief Financial Officer (CFO) will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutical industry in consumer goods, which he hasmaintained. The company has named Cecile Guegan, currently appointed as Senior Vice President, Finance, Global Biopharmaceutical Business, will act as Interim CFO, effective from August 16, while the company will conduct a comprehensive internal and external search for its new CFO role. Both Dave and Cecile will work together to ensure a seamless transition.

Chairman and Chief Executive Officer of Pfizer Albert Bourla said “Dave has been a steady and trusted steward of Pfizer’s financial health, and we are grateful for his leadership, especially during some of the most important business transactions in our recent history, including Seagen, Biohaven, and Metsera, that will serve Pfizer well for years to come. We wish him the very best as he returns to the consumer goods industry,”. He also added “Given Cecile’s deep institutional knowledge and financial acumen, I have every confidence in her ability to lead Pfizer’s finance organization and keep us focused on what matters most – executing our strategy and delivering for patients and shareholders.”

Companies interim CFO Cecile holds a Master in Business degree from Brest Business School and she also has more than two decades of experience at Pfizer, amassing deep global financial experience leading finance across a wide range of complex and strategic portfolios, research and development, and several regions. In her current role, she is directly responsible for the financial operations and reporting of Pfizer’s biopharmaceutical business across all therapeutic areas and geographies. She has strong financial judgement and a proven track record of leading important enterprise initiatives, including the integration of Seagen into Pfizer in 2024.

Written by: Pramit Hazra

Graphics by: Pramit Hazra

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

MSD Inaugurates New Technology Centre in Hyderabad to Drive Global Healthcare Innovation and Digital Capabilities

MSD (Merck & Co., Inc.), one of the world's leading global life sciences companies, has officially inaugurated its...

Bharat Technology Announces BT-PHARMACON 2K26 with Focus on Indigenous Pharma Innovation

Bharat Technology is set to organise BT-PHARMACON 2K26, an ANRF-sponsored national conference on September 26–27, 2026, at the Eastern Zonal...

ChrysCapital to Acquire 20-25% Stake in Linux Laboratories for ₹600 Crore

Private equity firm ChrysCapital is all set to acquire a strategic stake in Linux Laboratories, a Chennai-based specialty pharmaceutical company focused on central nervous...

India Spotlights Massive Health Workforce Expansion at WHO RC79; SEARO Adopts Historic Dili Declaration

The Ministerial Roundtable addressing on"Human Resources for Health: Equity in Specialized Care" at the 79th Session of the WHO Regional...